Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Antiviral Res. 2013 Apr 8;98(3):432–440. doi: 10.1016/j.antiviral.2013.03.023

Table 4.

Pharmacokinetic properties in rats

Dose IV/PO/IM/IP (mg/kg) AUC IV/PO/IM/IP (μg*h/mL) C0 IV (μg/mL) T1/2 IV (h) CL IV (L/h/kg) Vd IV (L/kg) Cmax PO/IM/IP (μg/ml) Tmax PO/IM/IP (h) F PO/IM/IP %
11029 5/25/ND/ND 1990/9180/ND/ND 1.62 1.44 2.54 3.1 1.34/ND/ND 4.17/ND/ND 92/ND/ND
17028 5/25/ND/ND 1540/903/ND/ND 1.66 0.88 3.34 3.0 0.18/ND/ND 1.56/ND/ND 12/ND/ND
19029 5/75/5/5 1383/945/1839/983 1.79 1.2 3.49 3.0 0.26/1.23/1.33 2.1/0.1/ 0.17 4.6/71/133

AUC, Area under the concentration vs time curve; C0, Initial blood concentration after IV dose; CL, plasma clearance; Vd, Volume of distribution; Cmax, maximum concentration in systemic circulation following dose; Tmax, time of Cmax; T1/2, time for blood concentration to reduce by half; F, percent of dose reaching systemic circulation unchanged. ND, not determined. 3 animals were used for each of the 11029 and 17028 study; 6 animals were used for 19029 study.